• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

CORRECTING and REPLACING Biosystemix Provides Advanced Data Mining and Predictive Modeling As an S2K Program Partner for the Development of Personalized Medicine Models in Immune Diseases

Posted on: Monday, 21 June 2004, 06:00 CDT

S2K's URL in the first graph should read www.s2kgenome.ca (sted www.s2k.genome.ca).

The corrected release reads:

BIOSYSTEMIX PROVIDES ADVANCED DATA MINING AND PREDICTIVE MODELING AS AN S2K PROGRAM PARTNER FOR THE DEVELOPMENT OF PERSONALIZED MEDICINE MODELS IN IMMUNE DISEASES

Biosystemix (www.biosystemix.com) joins S2K (www.s2kgenome.ca) as partner to develop data-driven computational models that predict disease susceptibility and progression, and therapeutic response. Funded by Genome Canada and Genome Quebec, S2K's program, "Functional Genomics, Pharmacogenomics and Proteomics of the Immune Response in Health and Immune Related Disorders," brings leading experts, institutions, and private sector efforts into a significant partnership to advance fundamental scientific understanding of immune dysfunction, and generate intellectual property for effective diagnostic and therapeutic agents including vaccines.

Biosystemix employs field-advancing data mining algorithms to discover complex relationships that link predictive marker sets to critical clinical outcomes and phenotypes. "The complexity of the immunological response often involves the combined action of multiple cellular and molecular effectors," explains Dr. Larry Greller, CSO of Biosystemix. "Our pattern analysis methods capture the combinatorial and nonlinear relationships required for the effective discovery of these complex disease markers and mechanistic regulators."

S2K academic and clinical laboratory associates generate complex arrays of data (gene expression, proteomics, and cellular immune response) regarding HIV and HCV infection, rheumatoid arthritis, and transplant rejection. Dr. Rafick-Pierre Sekaly, S2K Scientific Director, explains, "We aim to progress our understanding of these leading causes of mortality and morbidity through the application of cutting-edge technologies for molecular immune response profiling."

Within the Biosystemix-S2K partnership, Biosystemix will provide essential expertise to integrate complex volumes of data by applying advanced data-driven analysis solutions to extract key clinical, cellular, genomic, and molecular relationships leading to predictive molecular markers and models. Through comprehensive reverse engineering and mathematical modeling workflows, Biosystemix accomplishes integrations of data-driven markers into functional models of immune response and signaling networks.

"We are looking to Biosystemix," Dr. Sekaly adds, "to mine this combined, clinically- and experimentally-derived information for better diagnostic and prognostic markers of these disorders and diseases, and to integrate this knowledge into a systems model of immunological dysfunction." To advance personalized medicine, S2K seeks to develop significant individualized therapeutics. Resulting intellectual property will form the basis of commercial products, such as diagnostic and prognostic markers, novel therapeutic targets and vaccines, and data-driven models of immune regulation and dysfunction.

Biosystemix experts work directly with S2K scientists and management to define the pivotal scientific and clinical questions that guide computational discovery. Dr. Abdelkader Yachou, S2K Program Manager, says, "We are looking forward to working closely with Biosystemix as a strategic partner, and would like to welcome Dr. Greller to the S2K Research Management Committee and Dr. Roland Somogyi to the S2K Steering Committee."

More News in this Category